Patents by Inventor Kenneth Koblan

Kenneth Koblan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220062229
    Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
    Type: Application
    Filed: April 6, 2021
    Publication date: March 3, 2022
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
  • Patent number: 11129807
    Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: September 28, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
  • Publication number: 20200129477
    Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
    Type: Application
    Filed: February 16, 2018
    Publication date: April 30, 2020
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Seth HOPKINS, Kenneth KOBLAN, Antony LOEBEL, Ajay OGIRALA
  • Publication number: 20060003985
    Abstract: A T-type calcium channel antagonist is useful, alone or in combination with other agents, for inducing sleep and enhancing and improving the quality of sleep, in particular by increasing sleep efficiency and augmenting sleep maintenance.
    Type: Application
    Filed: October 15, 2003
    Publication date: January 5, 2006
    Inventors: John Renger, Kenneth Koblan